Cargando…

Revesz syndrome revisited

BACKGROUND: Revesz syndrome (RS) is an extremely rare variant of dyskeratosis congenita (DKC) with only anecdotal reports in the literature. METHODS: To further characterize the typical features and natural course of the disease, we screened the English literature and summarized the clinical and epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Karremann, Michael, Neumaier-Probst, Eva, Schlichtenbrede, Frank, Beier, Fabian, Brümmendorf, Tim H., Cremer, Friedrich W., Bader, Peter, Dürken, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583287/
https://www.ncbi.nlm.nih.gov/pubmed/33097095
http://dx.doi.org/10.1186/s13023-020-01553-y
_version_ 1783599370323623936
author Karremann, Michael
Neumaier-Probst, Eva
Schlichtenbrede, Frank
Beier, Fabian
Brümmendorf, Tim H.
Cremer, Friedrich W.
Bader, Peter
Dürken, Matthias
author_facet Karremann, Michael
Neumaier-Probst, Eva
Schlichtenbrede, Frank
Beier, Fabian
Brümmendorf, Tim H.
Cremer, Friedrich W.
Bader, Peter
Dürken, Matthias
author_sort Karremann, Michael
collection PubMed
description BACKGROUND: Revesz syndrome (RS) is an extremely rare variant of dyskeratosis congenita (DKC) with only anecdotal reports in the literature. METHODS: To further characterize the typical features and natural course of the disease, we screened the English literature and summarized the clinical and epidemiological features of previously published RS cases. In addition, we herein describe the first recorded patient in central Europe. RESULTS: The literature review included 18 children. Clinical features are summarized, indicating a low prevalence of the classical DKC triad. All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4–1.6). Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years; 95% CI 0.7–1.5). The incidence of seizures was low and was present in an estimated 20% of patients. The onset of seizures was exclusively during early childhood. The Kaplan–Meier estimate of survival was dismal (median survival 6.5 years; 95% CI 3.6–9.4), and none of the patients survived beyond the age of 12 years. Stem cell transplantation (SCT) was performed in eight children, and after a median of 22 months from SCT four of these patients were alive at the last follow up visit. CONCLUSION: RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients. Survival is dismal, but stem cell transplantation may be performed successfully and might improve prognosis in the future.
format Online
Article
Text
id pubmed-7583287
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75832872020-10-26 Revesz syndrome revisited Karremann, Michael Neumaier-Probst, Eva Schlichtenbrede, Frank Beier, Fabian Brümmendorf, Tim H. Cremer, Friedrich W. Bader, Peter Dürken, Matthias Orphanet J Rare Dis Review BACKGROUND: Revesz syndrome (RS) is an extremely rare variant of dyskeratosis congenita (DKC) with only anecdotal reports in the literature. METHODS: To further characterize the typical features and natural course of the disease, we screened the English literature and summarized the clinical and epidemiological features of previously published RS cases. In addition, we herein describe the first recorded patient in central Europe. RESULTS: The literature review included 18 children. Clinical features are summarized, indicating a low prevalence of the classical DKC triad. All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4–1.6). Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years; 95% CI 0.7–1.5). The incidence of seizures was low and was present in an estimated 20% of patients. The onset of seizures was exclusively during early childhood. The Kaplan–Meier estimate of survival was dismal (median survival 6.5 years; 95% CI 3.6–9.4), and none of the patients survived beyond the age of 12 years. Stem cell transplantation (SCT) was performed in eight children, and after a median of 22 months from SCT four of these patients were alive at the last follow up visit. CONCLUSION: RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients. Survival is dismal, but stem cell transplantation may be performed successfully and might improve prognosis in the future. BioMed Central 2020-10-23 /pmc/articles/PMC7583287/ /pubmed/33097095 http://dx.doi.org/10.1186/s13023-020-01553-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Karremann, Michael
Neumaier-Probst, Eva
Schlichtenbrede, Frank
Beier, Fabian
Brümmendorf, Tim H.
Cremer, Friedrich W.
Bader, Peter
Dürken, Matthias
Revesz syndrome revisited
title Revesz syndrome revisited
title_full Revesz syndrome revisited
title_fullStr Revesz syndrome revisited
title_full_unstemmed Revesz syndrome revisited
title_short Revesz syndrome revisited
title_sort revesz syndrome revisited
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583287/
https://www.ncbi.nlm.nih.gov/pubmed/33097095
http://dx.doi.org/10.1186/s13023-020-01553-y
work_keys_str_mv AT karremannmichael reveszsyndromerevisited
AT neumaierprobsteva reveszsyndromerevisited
AT schlichtenbredefrank reveszsyndromerevisited
AT beierfabian reveszsyndromerevisited
AT brummendorftimh reveszsyndromerevisited
AT cremerfriedrichw reveszsyndromerevisited
AT baderpeter reveszsyndromerevisited
AT durkenmatthias reveszsyndromerevisited